TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA.

IF 0.7 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
Acta Endocrinologica-Bucharest Pub Date : 2023-07-01 Epub Date: 2024-02-01 DOI:10.4183/aeb.2023.339
E A Giraldi, A Saindane, G Pradilla, V Biousse, A G Ioachimescu
{"title":"TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA.","authors":"E A Giraldi, A Saindane, G Pradilla, V Biousse, A G Ioachimescu","doi":"10.4183/aeb.2023.339","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dopamine agonists (DA) are first line treatment for prolactinomas. Optic chiasm herniation can rarely occur during therapy, while brain herniation is very uncommon.</p><p><strong>Case reports: </strong>A 34 yo woman presented with headaches and vision changes. Prolactin (PRL) was 4300 ng/mL. MRI showed a 4.5 cm pituitary adenoma with chiasm compression. After 3 months, PRL decreased to 201 ng/mL while patient was taking CAB 0.75 mg twice a week. MRI showed ~30% tumor reduction with medial temporal lobe herniation and encephalocele. CAB was stopped and she underwent surgical debulking and encephalocele repair. Histopathology confirmed prolactin tumor. CAB 0.75 mg twice a week was resumed.A 50 yo man had incidental detection of a sellar mass after trauma. MRI showed 3.6 cm tumor with minimal contact of right optic nerve, and PRL 3,318 ng/ml. He received CAB 0.5mg twice a week with PRL improvement to 26 ng/mL after 1 month. After 2 months ophthalmology exam showed new left superotemporal depression. PRL was 68 ng/mL and MRI showed 35% mass reduction and new inferior displacement tethering of the chiasm. CAB dose was decreased to 0.25 mg twice a week.</p><p><strong>Conclusion: </strong>Our cases illustrate that rapid biochemical and radiographic response to DA therapy in large prolactinomas warrants close clinical and neuro-ophthalmologic follow-up. We recommend repeating the MRI 3 months after initiation of DA therapy or sooner in case of new mass effect manifestations. Decision regarding DA dose reduction or chiasmopexy for visual field deficits needs to be multi-disciplinary and on a case-to-case basis.</p>","PeriodicalId":50902,"journal":{"name":"Acta Endocrinologica-Bucharest","volume":"19 3","pages":"339-344"},"PeriodicalIF":0.7000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863970/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Endocrinologica-Bucharest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4183/aeb.2023.339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Dopamine agonists (DA) are first line treatment for prolactinomas. Optic chiasm herniation can rarely occur during therapy, while brain herniation is very uncommon.

Case reports: A 34 yo woman presented with headaches and vision changes. Prolactin (PRL) was 4300 ng/mL. MRI showed a 4.5 cm pituitary adenoma with chiasm compression. After 3 months, PRL decreased to 201 ng/mL while patient was taking CAB 0.75 mg twice a week. MRI showed ~30% tumor reduction with medial temporal lobe herniation and encephalocele. CAB was stopped and she underwent surgical debulking and encephalocele repair. Histopathology confirmed prolactin tumor. CAB 0.75 mg twice a week was resumed.A 50 yo man had incidental detection of a sellar mass after trauma. MRI showed 3.6 cm tumor with minimal contact of right optic nerve, and PRL 3,318 ng/ml. He received CAB 0.5mg twice a week with PRL improvement to 26 ng/mL after 1 month. After 2 months ophthalmology exam showed new left superotemporal depression. PRL was 68 ng/mL and MRI showed 35% mass reduction and new inferior displacement tethering of the chiasm. CAB dose was decreased to 0.25 mg twice a week.

Conclusion: Our cases illustrate that rapid biochemical and radiographic response to DA therapy in large prolactinomas warrants close clinical and neuro-ophthalmologic follow-up. We recommend repeating the MRI 3 months after initiation of DA therapy or sooner in case of new mass effect manifestations. Decision regarding DA dose reduction or chiasmopexy for visual field deficits needs to be multi-disciplinary and on a case-to-case basis.

在多巴胺受体激动剂治疗催乳素瘤期间出现颞叶疝和脊髓病。
背景:多巴胺受体激动剂(DA多巴胺受体激动剂(DA)是治疗泌乳素瘤的一线药物。在治疗过程中,视交叉疝很少发生,而脑疝则非常罕见:一名 34 岁的女性因头痛和视力改变前来就诊。泌乳素(PRL)为 4300 纳克/毫升。核磁共振成像显示垂体腺瘤长 4.5 厘米,压迫脑脊。3 个月后,PRL 降至 201 纳克/毫升,患者服用 CAB 0.75 毫克,每周两次。核磁共振成像显示肿瘤缩小了约30%,并伴有颞叶内侧疝和脑积水。患者停用了 CAB,并接受了手术切除和脑包膜修复。组织病理学证实为泌乳素瘤。一名 50 岁的男子在外伤后偶然发现蝶窦肿块。核磁共振成像显示肿瘤长 3.6 厘米,与右视神经接触极少,PRL 为 3318 纳克/毫升。他接受了每周两次、每次 0.5 毫克的 CAB 治疗,1 个月后 PRL 下降到 26 纳克/毫升。2 个月后,眼科检查发现新的左侧颞上凹陷。PRL为68纳克/毫升,核磁共振成像显示肿块缩小了35%,并出现了新的椎管下移系带。CAB 剂量降至 0.25 毫克,每周两次:我们的病例说明,大催乳素瘤对DA治疗的快速生化和影像学反应需要密切的临床和神经眼科随访。我们建议在开始接受 DA 治疗 3 个月后重复 MRI 检查,如果出现新的肿块效应表现,则应尽早进行 MRI 检查。关于减少 DA 剂量或视交叉切除术治疗视野缺损的决定,需要根据具体情况由多学科共同做出。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Endocrinologica-Bucharest
Acta Endocrinologica-Bucharest 医学-内分泌学与代谢
CiteScore
1.30
自引率
20.00%
发文量
53
审稿时长
6-12 weeks
期刊介绍: Acta Endocrinologica (Buc) is an international journal covering the fields of basic and clinical Endocrinology, Neuroendocrinology, Reproductive Medicine, Chronobiology, Human Ethology published quarterly Acta Endocrinologica (Buc) is the official international journal of the Romanian Society for Endocrinology. It continues the former Romanian Journal of Endocrinology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信